Making Monoclonal Antibody Development a SURE thing with SUREmAb™
With optimized processes for efficiency and speed, SUREmAb delivers high titers with lower-cost workflows.
Built on the SUREtechnology Platform, SUREmAb shortens development and manufacturing for monoclonal antibodies (mAbs). It enables RCB development in as little as 9 weeks* and drug substance release in 11 months*. Specifically designed for accelerated, efficient mAb development that is robust and secured, SUREmAb projects achieve high titers of up to 10 g/L with a streamlined, lower-cost workflow that delivers the data and insights you need, the reliability and performance you expect, and the global regulatory compliance you require.
KBI Biopharma's SUREmAb offering is built on the robustness of the SUREtechnology Platform, delivering the quality you expect with a streamlined workflow for straightforward projects. Simple mAb development is a SURE thing with our rapid solution that preemptively navigates technical hurdles for the same quality under accelerated timelines.
With SUREmAb™,
you've met your Match
Efficiency and Speed, Simplified
In your mission to advance science and improve lives, every day matters. SUREmAb has been specifically designed to accelerate development timelines.
Optimized for Your Advantage
SUREmAb is engineered for robust, secured monoclonal antibody development, achieving high titers of up to 10 g/L and offering a streamlined, lower-cost workflow.
Proven Excellence You Can Trust
With over 15 years of mAb development experience, more than 150 unique therapeutic mAb projects, and 7 commercialized mAbs leveraging the SUREtechnology Platform, you're not just choosing a service - you're joining a legacy of success.
Innovation with Alleviation of Royalties
By continuing into clinical and commercial manufacturing with KBI, license fees will be waived, enabling you to make the most of our innovation without ongoing financial constraints.
